164 related articles for article (PubMed ID: 22134100)
1. Different response rates between palmoplantar involvement and diffuse plaque psoriasis in patients treated with infliximab.
Brunasso AM; Puntoni M; Delfino C; Massone C
Eur J Dermatol; 2012; 22(1):133-5. PubMed ID: 22134100
[No Abstract] [Full Text] [Related]
2. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study.
Bissonnette R; Poulin Y; Guenther L; Lynde CW; Bolduc C; Nigen S
J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1402-8. PubMed ID: 21349113
[TBL] [Abstract][Full Text] [Related]
3. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
Kamili QU; Miner A; Hapa A; Menter A
J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of hand and foot psoriasis with infliximab.
Di Lernia V; Guareschi E
Dermatol Online J; 2010 Jul; 16(7):8. PubMed ID: 20673536
[TBL] [Abstract][Full Text] [Related]
5. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD
Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
[TBL] [Abstract][Full Text] [Related]
6. Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement.
van Lingen RG; van Erp PE; Seyger MM; de Jong EM; de Boer-van Huizen RT; Driessen RJ; van de Kerkhof PC
Acta Derm Venereol; 2009; 89(5):518-20. PubMed ID: 19734982
[No Abstract] [Full Text] [Related]
7. Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
Lewis TG; Tuchinda C; Lim HW; Wong HK
J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108
[TBL] [Abstract][Full Text] [Related]
8. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis.
Krüger-Krasagakis S; Galanopoulos VK; Giannikaki L; Stefanidou M; Tosca AD
Br J Dermatol; 2006 Mar; 154(3):460-6. PubMed ID: 16445776
[TBL] [Abstract][Full Text] [Related]
10. Three years' experience with infliximab in recalcitrant psoriasis.
Ahmad K; Rogers S
Clin Exp Dermatol; 2006 Sep; 31(5):630-3. PubMed ID: 16901301
[TBL] [Abstract][Full Text] [Related]
11. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
Torii H; Nakagawa H;
J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
[TBL] [Abstract][Full Text] [Related]
12. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
[TBL] [Abstract][Full Text] [Related]
14. Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab.
Wozel G; Vitez L
Acta Derm Venereol; 2008; 88(2):169-70. PubMed ID: 18311451
[No Abstract] [Full Text] [Related]
15. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
[TBL] [Abstract][Full Text] [Related]
16. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial.
Reich K; Ortonne JP; Kerkmann U; Wang Y; Saurat JH; Papp K; Langley R; Griffiths CE
Dermatology; 2010; 221(2):172-8. PubMed ID: 20628238
[TBL] [Abstract][Full Text] [Related]
17. Response of severe psoriasis to infliximab.
Mang R; Stege H; Ruzicka T; Krutmann J
Dermatology; 2002; 204(2):156-7. PubMed ID: 11937748
[No Abstract] [Full Text] [Related]
18. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.
Dalaker M; Bonesrønning JH
J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):277-82. PubMed ID: 19207642
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
[TBL] [Abstract][Full Text] [Related]
20. Infliximab monotherapy in psoriasis: a case of rapid clinical and histological response.
Vincek V; Jacob SE; Nassiri M; Herbert LM; Nadji M; Kerdel FA
Int J Dermatol; 2004 Apr; 43(4):303-8. PubMed ID: 15090021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
